IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v515y2014i7528d10.1038_nature13988.html
   My bibliography  Save this article

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Author

Listed:
  • Matthew M. Gubin

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Xiuli Zhang

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Heiko Schuster

    (Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany)

  • Etienne Caron

    (Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland)

  • Jeffrey P. Ward

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Takuro Noguchi

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Yulia Ivanova

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Jasreet Hundal

    (The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA)

  • Cora D. Arthur

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Willem-Jan Krebber

    (ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands)

  • Gwenn E. Mulder

    (ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands)

  • Mireille Toebes

    (The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands)

  • Matthew D. Vesely

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Samuel S. K. Lam

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Alan J. Korman

    (Bristol-Myers Squibb, 700 Bay Road)

  • James P. Allison

    (The University of Texas MD Anderson Cancer Center)

  • Gordon J. Freeman

    (Dana-Farber Cancer Institute, Harvard Medical School)

  • Arlene H. Sharpe

    (Harvard Medical School)

  • Erika L. Pearce

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Ton N. Schumacher

    (The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands)

  • Ruedi Aebersold

    (Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland
    Faculty of Science, University of Zurich, Zurich, 8093 Zurich, Switzerland)

  • Hans-Georg Rammensee

    (Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany)

  • Cornelis J. M. Melief

    (ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands
    Leiden University Medical Center, 2333ZA Leiden, The Netherlands)

  • Elaine R. Mardis

    (The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA
    Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • William E. Gillanders

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Maxim N. Artyomov

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

  • Robert D. Schreiber

    (Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA)

Abstract

A carcinogen-induced mouse tumour model is used here to show that mutant tumour-specific antigens are targets for CD8+ T-cell responses, mediating tumour regression after checkpoint blockade immunotherapy, and that these antigens can be used effectively in therapeutic vaccines; this advance potentially opens the door to personalized cancer vaccines.

Suggested Citation

  • Matthew M. Gubin & Xiuli Zhang & Heiko Schuster & Etienne Caron & Jeffrey P. Ward & Takuro Noguchi & Yulia Ivanova & Jasreet Hundal & Cora D. Arthur & Willem-Jan Krebber & Gwenn E. Mulder & Mireille T, 2014. "Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens," Nature, Nature, vol. 515(7528), pages 577-581, November.
    • Handle: RePEc:nat:nature:v:515:y:2014:i:7528:d:10.1038_nature13988
    DOI: 10.1038/nature13988
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature13988
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature13988?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jeppe Sejerø Holm & Samuel A. Funt & Annie Borch & Kamilla Kjærgaard Munk & Anne-Mette Bjerregaard & James L. Reading & Colleen Maher & Ashley Regazzi & Phillip Wong & Hikmat Al-Ahmadie & Gopa Iyer & , 2022. "Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    2. Stefanie Hiltbrunner & Lena Cords & Sabrina Kasser & Sandra N. Freiberger & Susanne Kreutzer & Nora C. Toussaint & Linda Grob & Isabelle Opitz & Michael Messerli & Martin Zoche & Alex Soltermann & Mar, 2023. "Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    3. Nekisa Zakeri & Andrew Hall & Leo Swadling & Laura J. Pallett & Nathalie M. Schmidt & Mariana O. Diniz & Stephanie Kucykowicz & Oliver E. Amin & Amir Gander & Massimo Pinzani & Brian R. Davidson & Alb, 2022. "Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    4. Hakimeh Ebrahimi-Nik & Marmar Moussa & Ryan P. Englander & Summit Singhaviranon & Justine Michaux & HuiSong Pak & Hiroko Miyadera & William L. Corwin & Grant L. J. Keller & Adam T. Hagymasi & Tatiana , 2021. "Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope," Nature Communications, Nature, vol. 12(1), pages 1-11, December.
    5. John P. Finnigan & Jenna H. Newman & Yury Patskovsky & Larysa Patskovska & Andrew S. Ishizuka & Geoffrey M. Lynn & Robert A. Seder & Michelle Krogsgaard & Nina Bhardwaj, 2024. "Structural basis for self-discrimination by neoantigen-specific TCRs," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:515:y:2014:i:7528:d:10.1038_nature13988. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.